Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma (NASDAQ:SBFM) filed its Form 10-K for fiscal 2025, reporting $36.31 million revenue, a 4.1% increase versus 2024.

Rhea-AI Summary

Sunshine Biopharma (NASDAQ:SBFM) filed its Form 10-K for fiscal 2025, reporting $36.31 million revenue, a 4.1% increase versus 2024. Gross profit rose to $12.26 million while net loss widened to $5.98 million.

The company raised $2.46 million via a registered direct offering, launched nine new generic drugs, recorded a $1.75 million non‑cash impairment, and announced planned 2026 cost reductions of approximately $2–3 million.

Positive

• Gross profit increased to $12.26M (+14.9%)
• Registered direct offering raised $2.46M to support sales expansion
• Nine generic drug launches expanded portfolio across multiple therapeutic areas

Negative

• General & administrative expenses rose to $18.48M (+12.1%)
• Net loss increased to $5.98M (+16.6%)
• $1.75M impairment boosted 2025 non‑cash charges

Argus Apr 6 session

+11.54% close to close Open Argus

Details

News Market Reaction – SBFM

On Apr 6, the day this news came out, SBFM closed 11.54% above the previous close.

Data tracked by StockTitan Argus for the Apr 6 session.

Key Figures

2025 Revenue: $36.31M Revenue Growth: 4.1% 2025 Gross Profit: $12.26M +5 more

2025 Revenue

$36.31M

Fiscal 2025 vs $34.87M in 2024

Revenue Growth

4.1%

Fiscal 2025 vs 2024

2025 Gross Profit

$12.26M

Fiscal 2025 vs $10.67M in 2024

2025 Net Loss

$5.98M

Fiscal 2025 vs $5.13M in 2024

G&A Expenses 2025

$18.48M

Includes non-cash impairment; vs $16.48M in 2024

Impairment Charge

$1.75M

Non-cash, non-recurring intangible asset impairment in 2025

Capital Raised

$2.46M

Gross proceeds from registered direct offering for sales expansion

Planned Cost Reductions

$2M–$3M

Expected 2026 G&A expense reduction from initiatives

Previous Earnings Reports

5 past events · Latest: May 15

Same Type 5 events

1. May 15

   Q1 2025 earnings

   24h Move

   +13.6%

   Q1 2025 revenue up 18% to $8.9M with lower net loss year-over-year.

2. Apr 01

   2024 annual results

   24h Move

   +8.2%

   Fiscal 2024 revenue rose 45% to $34.9M while net loss widened modestly.

3. Nov 06

   Q3 2024 earnings

   24h Move

   -6.3%

   Q3 2024 showed strong sales growth but net loss increased 84% year-over-year.

4. Aug 19

   Q2 2024 earnings

   24h Move

   +5.8%

   Q2 2024 revenues up 67% with reduced net loss and higher shareholders’ equity.

5. May 21

   Q1 2024 earnings

   24h Move

   -17.8%

   Q1 2024 gross revenues up 54% and net loss improved, but shares fell sharply.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, non-covalent, plpro protease inhibitors, sars-cov-2, +3 more

7 terms

registered direct offering financial

"$2.46 million in gross proceeds raised through a registered direct offering..."

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

non-covalent medical

"a new series of orally active, non-covalent PLpro protease inhibitors..."

Non-covalent describes a type of interaction where molecules stick together through weak, reversible forces rather than forming permanent chemical bonds. For investors, non-covalent binding in drugs or diagnostics signals treatments that are often adjustable, shorter-acting, and potentially easier to reverse or fine-tune than covalent counterparts, which affects safety profiles, dosing strategies, patenting approaches and how a product may perform in the market.

plpro protease inhibitors medical

"non-covalent PLpro protease inhibitors that demonstrated dose-dependent antiviral activity..."

PLpro protease inhibitors are drugs that block the papain-like protease (PLpro), an enzyme some viruses use to process their proteins and weaken the body's defenses. For investors, they matter because a proven PLpro inhibitor can become a targeted antiviral treatment with clear regulatory and commercial implications, while setbacks in development influence clinical risk, approval timelines and potential market value—think of them as tools that jam a virus’s internal machinery.

sars-cov-2 medical

"dose-dependent antiviral activity in SARS-CoV-2-infected mice, strong potency..."

SARS-CoV-2 is the virus that causes the illness known as COVID-19; think of it as a biological engine that can start chains of sickness in people. It matters to investors because its spread and the measures taken to control it—such as changes to workforce availability, consumer demand, supply chains, travel, and healthcare spending—can quickly alter company revenues, costs and regulatory priorities, much like a sudden storm that affects many parts of an economy at once.

pharmacokinetics medical

"strong potency in cellular models, and favorable pharmacokinetics."

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

form 10-k regulatory

"announced the filing of its Annual Report on Form 10-K for the fiscal year..."

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

impairment charge financial

"driven by a non-cash, non-recurring impairment charge of $1.75 million..."

An impairment charge is an accounting write-down taken when a company determines an asset—like a building, patent, or investment—is worth less than its recorded value, similar to lowering the price tag on a used car when damage reduces its resale value. It matters to investors because it reduces reported profits and the company’s asset base, can signal business challenges or one-time losses, and may affect future earnings, creditworthiness, and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.

2025 Highlights

• Revenue of $36.3 million, representing a 4.1% increase compared to 2024.

• $2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations.

• Nine new generic prescription drugs launched, expanding the Company's portfolio in oncology, cardiovascular health, central nervous system disorders, and antimicrobials.

• Advancement of proprietary antiviral research, including a new series of orally active, non‑covalent PLpro protease inhibitors that demonstrated dose‑dependent antiviral activity in SARS‑CoV‑2‑infected mice, strong potency in cellular models, and favorable pharmacokinetics.

Management Commentary

"We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future," said Dr. Steve Slilaty, CEO. "Looking ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing our proprietary drug development programs to deliver more life‑saving medicines to the market."

Financial Summary (in millions)

	2025	2024
Revenue	$36.31	$34.87
Gross Profit	$12.26	$10.67
General & Administrative Expenses	$18.48	$16.48
Net Loss	$5.98	$5.13

The increase in General & Administrative Expenses in 2025 was primarily driven by a non‑cash, non‑recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, the Company's operating performance reflects a meaningful improvement over 2024.

In January 2026, Sunshine Biopharma implemented cost‑reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company's focus on achieving near‑term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.

About Sunshine Biopharma

Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:

• K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.

• PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.

Additional information is available at www.sunshinebiopharma.com.

Forward‑Looking Statements

This press release contains forward‑looking statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but are not limited to, those regarding the Company's financial performance, drug development activities, and future growth opportunities. Actual results may differ materially due to various risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. Readers are encouraged to review the Company's most recent SEC filings for additional information.

Contact:

Camille Sebaaly, CFO
Direct Line: 514‑814‑0464
camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Sunshine Biopharma (SBFM) fiscal 2025 revenue and net loss reported on April 6, 2026?

Sunshine Biopharma reported $36.31 million in revenue and a $5.98 million net loss for fiscal 2025. According to the company, revenue rose 4.1% year‑over‑year while net loss widened versus 2024.

How much did Sunshine Biopharma (SBFM) raise in the January 2026 registered direct offering and why?

The company raised $2.46 million in a registered direct offering to support expansion of sales operations. According to the company, proceeds will help scale commercial efforts and portfolio growth.

What drove the increase in Sunshine Biopharma's (SBFM) general and administrative expenses in 2025?

A non‑cash, non‑recurring $1.75 million impairment to intangible assets largely drove higher G&A in 2025. According to the company, this charge materially increased reported expenses versus 2024.

What cost reductions did Sunshine Biopharma (SBFM) announce for 2026 and what are the expected savings?

Sunshine Biopharma implemented cost‑reduction initiatives expected to lower expenses by $2–3 million in 2026. According to the company, these actions target general and administrative expense reductions to improve profitability.

How many new generic drugs did Sunshine Biopharma (SBFM) launch in 2025 and which areas do they cover?

Sunshine Biopharma launched nine new generic prescription drugs in 2025 across oncology, cardiovascular, CNS disorders, and antimicrobials. According to the company, these launches expand its commercial portfolio.

What progress did Sunshine Biopharma (SBFM) report on its antiviral research in 2025?

The company advanced proprietary antivirals, noting orally active, non‑covalent PLpro inhibitors with dose‑dependent activity in SARS‑CoV‑2 infected mice. According to the company, candidates showed cellular potency and favorable pharmacokinetics.